B.O.S.S. Retirement Advisors LLC Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

B.O.S.S. Retirement Advisors LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 626.2% during the 2nd quarter, Holdings Channel reports. The firm owned 4,241 shares of the company’s stock after buying an additional 3,657 shares during the quarter. B.O.S.S. Retirement Advisors LLC’s holdings in Eli Lilly and Company were worth $1,989,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Telemus Capital LLC raised its position in shares of Eli Lilly and Company by 2.1% during the 2nd quarter. Telemus Capital LLC now owns 2,857 shares of the company’s stock valued at $1,340,000 after buying an additional 58 shares in the last quarter. McLean Asset Management Corp raised its position in shares of Eli Lilly and Company by 1.8% during the 2nd quarter. McLean Asset Management Corp now owns 1,439 shares of the company’s stock valued at $675,000 after buying an additional 26 shares in the last quarter. AE Wealth Management LLC raised its position in shares of Eli Lilly and Company by 46.2% during the 2nd quarter. AE Wealth Management LLC now owns 82,931 shares of the company’s stock valued at $38,893,000 after buying an additional 26,195 shares in the last quarter. Fragasso Group Inc. raised its position in shares of Eli Lilly and Company by 1,029.6% during the 2nd quarter. Fragasso Group Inc. now owns 7,071 shares of the company’s stock valued at $3,316,000 after buying an additional 6,445 shares in the last quarter. Finally, CVA Family Office LLC raised its position in shares of Eli Lilly and Company by 3.8% during the 2nd quarter. CVA Family Office LLC now owns 2,418 shares of the company’s stock valued at $1,134,000 after buying an additional 88 shares in the last quarter. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Eli Lilly and Company Trading Down 2.7 %

Shares of NYSE:LLY opened at $575.66 on Friday. The business’s 50-day moving average is $512.56 and its 200 day moving average is $438.41. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87. Eli Lilly and Company has a 1 year low of $296.32 and a 1 year high of $601.84. The firm has a market capitalization of $546.47 billion, a P/E ratio of 80.06, a P/E/G ratio of 2.47 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. The business had revenue of $8.31 billion for the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The company’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.25 earnings per share. On average, research analysts predict that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.

Insider Buying and Selling

In related news, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now directly owns 7,760 shares in the company, valued at approximately $4,586,004.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 37,660 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total transaction of $20,590,670,905.00. Following the completion of the sale, the insider now directly owns 100,275,279 shares in the company, valued at approximately $54,825,684,274,988.30. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The disclosure for this sale can be found here. Insiders sold 1,010,309 shares of company stock worth $21,095,701,670 in the last three months. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on LLY shares. Citigroup upped their price target on shares of Eli Lilly and Company from $360.00 to $525.00 and gave the company a “buy” rating in a report on Wednesday, July 26th. Royal Bank of Canada upped their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Morgan Stanley upped their price target on shares of Eli Lilly and Company from $617.00 to $640.00 and gave the company an “overweight” rating in a report on Tuesday, September 5th. Credit Suisse Group upped their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, August 9th. Finally, Argus upped their price target on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.